Skip to content
Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

Harmony Biosciences Holdings, Inc. (HRMY)

A forensic read on Harmony Biosciences Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

B · Sound & dependable
Forensic grade
Safe
Financial health
7.2
Distress distance
Clean
Earnings quality
20.8%
ROE
21.5%
Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Harmony Biosciences Holdings, Inc. earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 7.2, placing it in the Safe zone. 0 forensic signals listed from the 9 signals read.

Key fundamentals

Latest Revenue$868.5M
Revenue Growth YoY+21.5%
Revenue CAGR (2yr)+22.2%
Net Margin18.3%
Free Cash Flow$347.9M
Return on Equity20.8%
Debt / Equity0.19x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Harmony Biosciences Holdings, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.